COMMUNIQUÉS West-GlobeNewswire

Basel Medical Group Completes Acquisition of Bethesda Medical to Strengthen Healthcare Ecosystem in Singapore and Southeast Asia
30/04/2025
Singapore , April 30, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq: BMGL) , today announced the closing of the acquisition of Bethesda Medical Pte. Ltd., a leading Singapore-based healthcare provider [...]
Rakovina Strengthens Board with Appointments of Yevgeniy Meshcherekov and David Kideckel
30/04/2025
VANCOUVER, British Columbia, April 29, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)- [...]
Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025
30/04/2025
NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the [...]
iTeos publie les résultats financiers de son premier trimestre 2025 et fait le point sur ses activités
29/04/2025
- Données de haut niveau provisoires issues de l’essai GALAXIES Lung-201, et plus de 240 patients attendus au deuxième trimestre 2025 - Données provisoires issues des essais GALAXIES H&N-202 et TIG-006 HNSCC, et [...]
Cytek® Biosciences Brings Cutting-Edge Cell Analysis Solutions to CYTO and IMMUNOLOGY2025
29/04/2025
Company to Conduct Demonstrations, Educational Workshops and Tutorials at Key Industry Events FREMONT, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Continuing its commitment to advancing cell analysis, Cytek Biosciences, [...]
Nuo Therapeutics Announces Exclusive Private Label Distribution Agreement with Smith+Nephew
29/04/2025
HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”), a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging opportunities in [...]
Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting
29/04/2025
Phase 1a dose-escalation study data update: treatment with NXP900 resulted in exposure levels leading to robust pharmacodynamic responses across a range of tolerated doses; NXP900 has an acceptable safety profile, dose [...]
CooperCompanies Announces Release Date for Second Quarter 2025
29/04/2025
SAN RAMON, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today it will report second quarter 2025 financial results on Thursday, May 29, 2025, at 4 [...]
Certara to Participate in Upcoming Investor Conferences
29/04/2025
RADNOR, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor [...]
Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement
29/04/2025
-- Nasdaq Compliance Follows ADS Ratio Change to Secure Company’s Public Listing -- -- Amarin Remains Focused on Maximizing the Global Value of VASCEPA/VAZKEPA – DUBLIN and BRIDGEWATER, N.J., April 29, 2025 (GLOBE [...]
The Ensign Group Reports First Quarter 2025 Results; Raises Annual Earnings and Revenue Guidance
29/04/2025
Conference Call and Webcast scheduled for tomorrow, April 30, 2025 at 10:00 am PT SAN JUAN CAPISTRANO, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign ( [...]
Senseonics Holdings, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for May 8, 2025 at 4:30 P.M. Eastern Time
29/04/2025
GERMANTOWN, Md., April 29, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose [...]
Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting
29/04/2025
ERAS-0015 and ERAS-4001 showed robust anti-tumor activity as monotherapy and combination therapy First-in-class examples of direct SHOC2 binders and modulators of SMP complex assembly identified with potential to block [...]
Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis
29/04/2025
Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis The Phase 3 ABTECT trials (Studies 105 and 106) evaluating obefazimod in patients [...]
PROCEPT BioRobotics® to Attend Four Upcoming Investor Conferences in May & June
29/04/2025
SAN JOSE, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, [...]
BridgeBio Reports First Quarter 2025 Financial Results and Business Updates
29/04/2025
- $36.7 million in first full quarter of U.S. Attruby™ net product revenue and as of April 25, 2025, 2,072 unique patient prescriptions written by 756 unique prescribers - Observational run-in study for [...]
BeautyHealth to Report First Quarter 2025 Financial Results on May 8, 2025
29/04/2025
LONG BEACH, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- The Beauty Health Company (NASDAQ:SKIN), home to flagship brand Hydrafacial™, today announced it will report first quarter 2025 financial results after market close [...]
Artios Pharma Reports Differentiated Clinical Activity in STELLA Phase 1/2a Study for Lead Program ART0380 at the American Association for Cancer Research (AACR) Annual Meeting 2025
29/04/2025
ART0380 in combination with low-dose irinotecan demonstrated a 50% confirmed overall response rate (cORR) in patients with Ataxia-Telangiectasia Mutated (ATM)-negative 1 solid tumors at the recommended Phase 2 dose ( [...]
Nouscom Presents Positive Final Results from Completed Phase Ib/II Study of Neoantigen Immunotherapy NOUS-209 at AACR 2025, Demonstrating a Highly Potent and Durable Immune Response in Lynch Syndrome Carriers
29/04/2025
Lynch Syndrome (LS) is a common hereditary condition that significantly increases the lifetime risk of cancer, especially colorectal and endometrial, to as high as 80% NOUS-209 is an off-the-shelf immunotherapy designed [...]

Pages